Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Operating Leases (2019 - 2025)

Benitec Biopharma has reported Operating Leases over the past 7 years, most recently at $987000.0 for Q4 2025.

  • Quarterly results put Operating Leases at $987000.0 for Q4 2025, up 620.44% from a year ago — trailing twelve months through Dec 2025 was $987000.0 (up 620.44% YoY), and the annual figure for FY2025 was $495000.0, up 74.3%.
  • Operating Leases reached $987000.0 in Q4 2025 per BNTC's latest filing, up from $817000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $987000.0 in Q4 2025 and bottomed at $62000.0 in Q1 2024.
  • Median Operating Leases over the past 5 years was $422500.0 (2022), compared with a mean of $478650.0.
  • The largest annual shift saw Operating Leases plummeted 82.49% in 2024 before it skyrocketed 888.71% in 2025.
  • Over 5 years, Operating Leases stood at $698000.0 in 2021, then fell by 1.86% to $685000.0 in 2022, then tumbled by 80.0% to $137000.0 in 2023, then changed by 0.0% to $137000.0 in 2024, then soared by 620.44% to $987000.0 in 2025.
  • Business Quant data shows Operating Leases for BNTC at $987000.0 in Q4 2025, $817000.0 in Q3 2025, and $495000.0 in Q2 2025.